CALA Calithera Biosciences, Inc.

-0.10  -1%
Previous Close 15.25
Open 15.25
Price To book 3.25
Market Cap 534.70M
Shares 35,294,000
Volume 693,944
Short Ratio 1.96
Av. Daily Volume 761,055

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 oral presentation at ASCO, June 5, 2017.
Solid tumors - cancer
Phase 1/2 enrolment commenced August 2016. Initial data due 2H 2017.
CB-839 + nivolumab
Renal cell carcinoma, malignant melanoma and non-small cell lung cancer

Latest News

  1. 5 Best Biotech Stocks of 2017 So Far
  2. Why Calithera Biosciences (CALA) Could Be Positioned for a Surge
  3. Calithera Biosciences to Participate in the JMP Securities 2017 Life Sciences Conference
  4. This Biotech Name Could Be Best In Breed For 2017
  5. Today's Research Reports on Stocks to Watch: Calithera Biosciences and Cerus Corporation
  6. How Calithera Biosciences Won Big With Its Cancer Treatment
  7. Calithera Biosciences Announces FDA Fast Track Designation Granted to CB-839 for Treatment of Patients with Renal Cell Carcinoma
  8. CB-1158 (INCB01158) Phase I Solid Tumor Data Presented at the American Society of Clinical Oncology Annual Meeting
  9. 3 Under-the-radar Momentum Plays
  10. Calithera Biosciences (CALA) Jumps: Stock Moves 17% Higher
  11. Today's Research Reports on Stocks to Watch: Tonix Pharmaceuticals and Calithera Biosciences
  12. Edited Transcript of CALA earnings conference call or presentation 9-May-17 8:30pm GMT
  13. Here's Why Calithera Biosciences Stock Gained as Much as 16.4% Today
  14. Bristol-Myers Squibb and Calithera Biosciences Expand Collaboration Evaluating Opdivo (nivolumab) in Combination with CB-839 into Non-Small Cell Lung Cancer and Melanoma
  15. Calithera reports 1Q loss
  16. Calithera Biosciences Reports First Quarter 2017 Financial Results and Recent Highlights
  17. Investor Network: Calithera Biosciences, Inc. to Host Earnings Call
  18. Calithera Biosciences to Report First Quarter 2017 Financial Results on Tuesday, May 9, 2017
  19. CB-1158 Phase I Data Accepted for an Oral Presentation at the ASCO Annual Meeting